Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.72 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9669395 | 0.88 | CYP3A4 (0.58) | CYP3A4CYP1A2CYP2D6CYP2C9NFKB1 | |
| SCHEMBL19220802 | 0.88 | CYP3A4 (0.56) | CYP3A4CYP1A2CYP2D6CYP2C9NFKB1 | |
| SCHEMBL17512967 | 0.86 | CYP3A4 (0.76) | CYP3A4CYP1A2CYP2D6CYP2C9NFKB1 | |
| SCHEMBL9669467 | 0.86 | CYP3A4 (0.56) | CYP3A4CYP1A2CYP2D6CYP2C9NFKB1 | |
| SCHEMBL9669136 | 0.85 | CYP3A4 (0.55) | CYP3A4CYP1A2CYP2D6CYP2C9NFKB1 | |
| SCHEMBL11658594 | 0.85 | CYP3A4 (0.70) | CYP3A4CYP1A2CYP2D6CYP2C9NFKB1 | |
| (S)-Alaproclate SCHEMBL23928818 | 0.85 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2D6CYP2C9NFKB1 | |
| Alaproclate SCHEMBL5784981 | 0.85 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2D6CYP2C9NFKB1 | |
| Alaproclate SCHEMBL29481071 | 0.85 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2D6CYP2C9NFKB1 | |
| SCHEMBL17512982 | 0.85 | CYP3A4 (0.61) | CYP3A4CYP1A2CYP2D6CYP2C9NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083839-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-03-14 | — | — | US | disclosed |
| EP-4225730-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | The Regents of the University of California (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076507-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20170226059-A1 | APOE4-TARGETED THERAPUTICS THAT INCREASE SIRT1 | BUCK INSTITUTE FOR RESEARCH ON AGING | 2017-08-10 | — | — | US | disclosed |
| US-20170226059-A1 | APOE4-TARGETED THERAPUTICS THAT INCREASE SIRT1 | BUCK INSTITUTE FOR RESEARCH ON AGING | 2017-08-10 | — | — | US | disclosed |
| US-20170226059-A1 | APOE4-TARGETED THERAPUTICS THAT INCREASE SIRT1 | BUCK INSTITUTE FOR RESEARCH ON AGING | 2017-08-10 | — | — | US | disclosed |
| EP-3183229-A1 | APOE4-TARGETED THERAPUTICS THAT INCREASE SIRT1 | The Regents Of The University Of California (US) | 2017-06-28 | — | — | EP | disclosed |
| WO-2016028910-A1 | APOE4-TARGETED THERAPUTICS THAT INCREASE SIRT1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-02-25 | — | — | WO | disclosed |
| WO-2016028910-A1 | APOE4-TARGETED THERAPUTICS THAT INCREASE SIRT1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226059-A1 | APOE4-TARGETED THERAPUTICS THAT INCREASE SIRT1 | SIRT1, PSEN2, PSEN1 | CYP3A4 4596/4885CYP1A2 4125/4885CYP2D6 4660/4885 |
| US-20240083839-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | PRMT8, SIRT1, PRMT3 | CYP3A4 4876/4885CYP1A2 4829/4885CYP2D6 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.